Emerging Cancer

Description:

Okay, so I got hit bad by Dendreon, but who didn't? It was worth it to take a chance, especially after the surprisingly positive AC recommendation. But hindsight is 20/20, and I was blinded by message board contributors who didn't see the writing on the wall that pointed towards an approvable letter. But all is not lost if you are a true DNDN long as I still believe that the therapy has potential, and the experience has opened me up to the emerging cancer field, which even has it's own index fund in HHJ. This portfolio keeps track of all the stocks in this field, hopefully separating the wheat from the chaff.

Most Viewed Portfolios

View All

Articles

3 Tech Stocks Under $10 Triggering Breakout Trades

09.19.14 | 08:21 AM

DELAFIELD, Wis. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percen...

Dividend Preview: 5 Dividend Stocks Ready to Pay You More

09.19.14 | 09:07 AM

BALTIMORE (Stockpickr) -- Don't get fooled by the flash of new all-time highs in the big stock indices; if you're not buying dividend names, you're...

More Articles
blog comments powered by Disqus
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter